Alaunos Therapeutics, Inc. (TCRT) reports developments as an early-stage biotechnology company focused on orally administered small-molecule therapeutics for obesity and related metabolic disorders. Recent updates center on ALN1003, a non-hormonal, non-incretin oral candidate evaluated in preclinical diet-induced obesity models, including body-weight, liver and metabolic biomarker findings.
Company news also reflects Alaunos's transition from earlier TCR-T cell therapy programs for solid tumors, including the TCR-T Library trial, the Sleeping Beauty cell engineering platform and the hunTR discovery platform. Recurring corporate updates include operating results, research spending, capital-structure actions, Nasdaq listing compliance and governance changes.
Alaunos Therapeutics, Inc. (TCRT) will announce its fourth-quarter financial results for 2021 on March 30, 2022, before U.S. market open. Following this, a conference call and webcast will be held at 8:30 a.m. ET for a corporate update and financial review. Investors can access the call by dialing in or through a live webcast on the company’s website. Alaunos specializes in oncology-focused cell therapies, leveraging its Sleeping Beauty gene transfer platform, and has collaborations with notable institutions like MD Anderson Cancer Center and the National Cancer Institute.
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced that CEO Kevin S. Boyle Sr. and VP of Research & Development Drew Deniger will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 9:20am ET. The presentation will be available via a live webcast on the company’s website, with an archived replay accessible for 30 days. Alaunos focuses on oncology cell therapies, developing T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer technology and targeting major tumor-related mutations.